BioCryst Stock Based Compensation from 2010 to 2024

BCRX Stock

USD 7.53 0.07 0.92%

BioCryst Pharmaceuticals Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation will likely drop to about 52.8 M in 2024. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals

Stock Based Compensation

First Reported

2000-12-31

Previous Quarter

13.2 M

Current Value

17.2 M

Quarterly Volatility

912.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 113.7 M or Selling General Administrative of 209.1 M, as well as many indicators such as Price To Sales Ratio of 3.3, Dividend Yield of 0.0 or Days Sales Outstanding of 59.59. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of BioCryst Pharmaceuticals Correlation against competitors.

For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.

Latest BioCryst Pharmaceuticals' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of BioCryst Pharmaceuticals over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. BioCryst Pharmaceuticals' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioCryst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Stock Based Compensation

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Stock Based Compensation

Timeline

BioCryst Stock Based Compensation Regression Statistics

	Arithmetic Mean	25,901,683
	Geometric Mean	15,926,920
	Coefficient Of Variation	108.49
	Mean Deviation	21,708,111
	Median	12,621,000
	Standard Deviation	28,100,396
	Sample Variance	789.6T
	Range	100.4M
	R-Value	0.17
	Mean Square Error	826T
	R-Squared	0.03
	Significance	0.55
	Slope	1,063,360
	Total Sum of Squares	11054.9T

BioCryst Stock Based Compensation History

	2024	52.8 M
	2023	55.6 M
	2022	44.7 M
	2021	34.6 M
	2020	14.8 M
	2019	17.7 M
	2018	9.4 M

Other Fundumenentals of BioCryst Pharmaceuticals

Stock Based Compensation To Revenue

BioCryst Pharmaceuticals Stock Based Compensation component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Short Term Investments	Common Stock	Current Deferred Revenue	Property Plant Equipment	Net Receivables	Net Tangible Assets	Long Term Debt	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.63	0.71	-0.94	0.91	0.95	1.0	-0.66	0.64	0.93	-0.3	0.87	0.79	-0.8	0.93	0.93	0.85	-0.65	-0.29	0.24	0.93	0.95	0.93
Total Stockholder Equity	-0.63		-0.07	0.58	-0.61	-0.44	-0.61	0.11	0.0	-0.66	0.43	-0.5	-0.22	0.27	-0.38	-0.47	-0.74	0.58	0.05	-0.07	-0.63	-0.65	-0.56
Net Debt	0.71	-0.07		-0.79	0.53	0.88	0.71	-0.69	0.95	0.65	-0.13	0.77	0.89	-0.9	0.9	0.74	0.49	-0.34	-0.33	0.34	0.59	0.6	0.68
Retained Earnings	-0.94	0.58	-0.79		-0.88	-0.95	-0.94	0.52	-0.77	-0.97	0.43	-0.89	-0.78	0.77	-0.91	-0.91	-0.87	0.67	0.36	-0.4	-0.8	-0.84	-0.93
Accounts Payable	0.91	-0.61	0.53	-0.88		0.83	0.92	-0.48	0.5	0.93	-0.34	0.79	0.63	-0.59	0.78	0.87	0.84	-0.6	-0.39	0.31	0.82	0.85	0.91
Total Liab	0.95	-0.44	0.88	-0.95	0.83		0.96	-0.74	0.8	0.89	-0.23	0.88	0.89	-0.9	0.99	0.95	0.76	-0.54	-0.39	0.26	0.87	0.89	0.92
Total Current Assets	1.0	-0.61	0.71	-0.94	0.92	0.96		-0.68	0.63	0.93	-0.27	0.87	0.8	-0.81	0.93	0.95	0.85	-0.64	-0.36	0.24	0.94	0.96	0.95
Short Term Debt	-0.66	0.11	-0.69	0.52	-0.48	-0.74	-0.68		-0.53	-0.43	-0.4	-0.63	-0.84	0.83	-0.8	-0.71	-0.39	0.16	0.29	0.08	-0.76	-0.74	-0.62
Short Term Investments	0.64	0.0	0.95	-0.77	0.5	0.8	0.63	-0.53		0.66	-0.16	0.74	0.8	-0.73	0.8	0.69	0.48	-0.41	-0.29	0.46	0.44	0.46	0.64
Common Stock	0.93	-0.66	0.65	-0.97	0.93	0.89	0.93	-0.43	0.66		-0.4	0.86	0.72	-0.64	0.82	0.89	0.9	-0.74	-0.37	0.46	0.77	0.82	0.94
Current Deferred Revenue	-0.3	0.43	-0.13	0.43	-0.34	-0.23	-0.27	-0.4	-0.16	-0.4		-0.19	0.13	0.09	-0.16	-0.16	-0.33	0.31	0.01	-0.14	-0.16	-0.18	-0.21
Property Plant Equipment	0.87	-0.5	0.77	-0.89	0.79	0.88	0.87	-0.63	0.74	0.86	-0.19		0.8	-0.74	0.86	0.82	0.79	-0.52	-0.27	0.38	0.75	0.77	0.8
Net Receivables	0.79	-0.22	0.89	-0.78	0.63	0.89	0.8	-0.84	0.8	0.72	0.13	0.8		-0.89	0.92	0.82	0.6	-0.42	-0.38	0.34	0.72	0.74	0.81
Net Tangible Assets	-0.8	0.27	-0.9	0.77	-0.59	-0.9	-0.81	0.83	-0.73	-0.64	0.09	-0.74	-0.89		-0.95	-0.81	-0.53	0.29	0.4	-0.08	-0.81	-0.81	-0.75
Long Term Debt	0.93	-0.38	0.9	-0.91	0.78	0.99	0.93	-0.8	0.8	0.82	-0.16	0.86	0.92	-0.95		0.93	0.7	-0.49	-0.39	0.24	0.87	0.88	0.88
Long Term Debt Total	0.93	-0.47	0.74	-0.91	0.87	0.95	0.95	-0.71	0.69	0.89	-0.16	0.82	0.82	-0.81	0.93		0.77	-0.56	-0.54	0.23	0.88	0.9	0.96
Capital Surpluse	0.85	-0.74	0.49	-0.87	0.84	0.76	0.85	-0.39	0.48	0.9	-0.33	0.79	0.6	-0.53	0.7	0.77		-0.73	-0.23	0.37	0.77	0.82	0.87
Deferred Long Term Liab	-0.65	0.58	-0.34	0.67	-0.6	-0.54	-0.64	0.16	-0.41	-0.74	0.31	-0.52	-0.42	0.29	-0.49	-0.56	-0.73		0.15	-0.63	-0.48	-0.53	-0.62
Long Term Investments	-0.29	0.05	-0.33	0.36	-0.39	-0.39	-0.36	0.29	-0.29	-0.37	0.01	-0.27	-0.38	0.4	-0.39	-0.54	-0.23	0.15		-0.25	-0.31	-0.34	-0.49
Short Long Term Debt	0.24	-0.07	0.34	-0.4	0.31	0.26	0.24	0.08	0.46	0.46	-0.14	0.38	0.34	-0.08	0.24	0.23	0.37	-0.63	-0.25		-0.02	0.04	0.32
Net Invested Capital	0.93	-0.63	0.59	-0.8	0.82	0.87	0.94	-0.76	0.44	0.77	-0.16	0.75	0.72	-0.81	0.87	0.88	0.77	-0.48	-0.31	-0.02		1.0	0.87
Net Working Capital	0.95	-0.65	0.6	-0.84	0.85	0.89	0.96	-0.74	0.46	0.82	-0.18	0.77	0.74	-0.81	0.88	0.9	0.82	-0.53	-0.34	0.04	1.0		0.9
Capital Stock	0.93	-0.56	0.68	-0.93	0.91	0.92	0.95	-0.62	0.64	0.94	-0.21	0.8	0.81	-0.75	0.88	0.96	0.87	-0.62	-0.49	0.32	0.87	0.9

Click cells to compare fundamentals

About BioCryst Pharmaceuticals Financial Statements

BioCryst Pharmaceuticals investors use historical fundamental indicators, such as BioCryst Pharmaceuticals' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Stock Based Compensation	55.6 M	52.8 M
Stock Based Compensation To Revenue	0.17	0.16

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for BioCryst Stock Analysis

When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioCryst Stock Based Compensation from 2010 to 2024

Latest BioCryst Pharmaceuticals' Stock Based Compensation Growth Pattern

BioCryst Stock Based Compensation Regression Statistics

BioCryst Stock Based Compensation History

Other Fundumenentals of BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Stock Based Compensation component correlations

About BioCryst Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for BioCryst Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY